BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

1:40 PM
 | 
May 18, 2018
 |  BioCentury  |  Finance

CellCentric’s magic trio

Why Morningside is backing CellCentric’s single-asset strategy

Five years after pivoting from target discovery to drug development, epigenetics play CellCentric Ltd. is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments. The company believes the undisclosed venture round will be enough to get the prostate cancer compound through clinical proof-of-concept studies.

Morningside first invested in CellCentric in 2007.

Morningside’s Jason Dinges said that at the time, CellCentric “was focused broadly on epigenetics, but was more using its biology expertise to identify interesting targets, then collaborate with partners to develop those targets to...

Read the full 445 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >